Anifrolumab Biosimilar - Research Grade

Human

IFNAR1

>1mg/ml

Human IgG1 (L351F/L352E/P448S)-Kappa

Anti-Mouse IFNAR1 (MAR1-5A3) In Vivo Antibody - Low Endotoxin (ICH1122)

https://www.imgt.org/mAb-DB/

ICH3002

P17181

Blue ice

ICH5130 is an unconjugated, non-therapeutic recombinant analog of anifrolumab, engineered around the same target, interferon-alpha/beta receptor subunit 1 (IFNAR1). It is supplied for research use only (RUO) and is not the clinical drug; it is not intended for human or veterinary use. Like the originator, it is a human IgG1-kappa built with the triple Fc mutation (L234F/L235E/P331S numbering here annotated L351F/L352E/P448S) that markedly reduces FcgammaR and complement engagement, so activity is driven by receptor binding rather than effector function. As an IFNAR1-directed binder it is useful as a positive control or benchmark reagent in receptor-blockade and type I interferon signaling assays, for antagonist-antibody characterization, epitope and competition studies, and as a tool in in-vitro and preclinical models of interferon biology. It is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg option) and in bulk milligram-to-gram quantities to support screening, assay development, and in-vivo standard workflows. Guidance provided for ichorbio to review. IFNAR1 (UniProt P17181) is one of two subunits of the heterodimeric type I interferon receptor; together with IFNAR2 it forms the signaling complex for all type I interferons, including the multiple IFN-alpha subtypes, IFN-beta, IFN-omega, IFN-epsilon and IFN-kappa. Ligand engagement brings IFNAR1 and IFNAR2 together, activating the receptor-associated Janus kinases TYK2 (on IFNAR1) and JAK1 (on IFNAR2). This drives phosphorylation of STAT1 and STAT2, assembly of the ISGF3 complex with IRF9, and transcription of interferon-stimulated genes. Type I IFN signaling shapes antiviral defense, innate and adaptive immunity, and a self-amplifying feedback loop. Sustained IFNAR1 signaling and an elevated interferon gene signature are implicated in autoimmune conditions such as systemic lupus erythematosus, making IFNAR1 a well-validated blockade target.

IFN-R-1, IFN-alpha/beta receptor 1, Cytokine receptor class-II member 1, Cytokine receptor family 2 member 1, CRF2-1, Type I interferon receptor 1, Interferon alpha/beta receptor 1, IFNAR

Detects human IFNAR1

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.